NASDAQ:KLRS | Free Cash Flow | Kalaris Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$11.58M
2025-12-31-$7.06M$17,000.00-$7.07M
2025-03-31-$7.44M
2024-12-31-$7.85M
2024-03-31-$4.52M
2023-12-31-$30.74M
2023-03-31-$32.12M
2022-12-31-$31.57M
2022-03-31-$46.48M
2021-12-31-$28.07M-$370,000.00-$28.44M
2021-03-31-$18.93M$75,000.00-$19M
2020-12-31-$21.09M
2020-03-31-$10.54M
2019-12-31-$8.87M$121,000.00-$8.99M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$38.37M$200,000.00-$38.57M
2024-12-31-$20.67M
2023-12-31-$124.45M
2022-12-31-$142.05M
2021-12-31-$106.32M$26,000.00-$106.35M
2020-12-31-$60.81M$235,000.00-$61.05M
2019-12-31-$20.16M$339,000.00-$20.49M